ALIAXIN EV Injection Solution for

What is ALIAXIN EV

ALIAXIN EV is a sterile injectable solution of **hyaluronic acid** administered via pre-filled syringes (2 × 1 mL). As a high–molecular-weight glycosaminoglycan resembling natural synovial fluid, it is typically used for viscosupplementation in osteoarthritis or as a dermal filler depending on formulation.

• Product type: Intra-articular or aesthetic injectable; used in orthopedics (e.g., knee osteoarthritis) and cosmetics.
• Therapeutic uses:
  • Knee pain relief in osteoarthritis via joint lubrication and cushioning :contentReference[oaicite:1]{index=1};
  • Dermal volume restoration (fine lines, facial contour) by water-binding and structural support :contentReference[oaicite:2]{index=2};
  • Potential use in ocular surgeries and mucosal hydration :contentReference[oaicite:3]{index=3}.
• Advantages: Biocompatible, biodegradable, and minimally immunogenic; provides mechanical support with a favorable safety profile :contentReference[oaicite:4]{index=4}.
• Limitations: Temporary effects (typically 3–6 months in joints); multiple injections may be needed; risk of mild local reaction :contentReference[oaicite:5]{index=5}.

In sum, ALIAXIN EV leverages the body’s own hyaluronan for therapeutic lubrication and volume enhancement in clinical and aesthetic applications.

How to use ALIAXIN EV

ALIAXIN EV should only be administered by trained healthcare professionals using strict aseptic techniques:

• Route: Intradermal (cosmetic) or intra-articular (orthopedic) depending on indication.
• Preparation: Inspect syringe, clean skin with alcohol (avoid quaternary ammonium disinfectants) :contentReference[oaicite:6]{index=6};
• Injection technique:
  • Dermal: small-volume micro/linear injections at targeted facial sites;
  • Joint: inject full 1 mL into knee/cartilage space; for bilateral treatment, use separate syringes :contentReference[oaicite:7]{index=7}.
• Dosing frequency:
  • Joints: weekly injections for 2–5 weeks depending on product (e.g., Synvisc 3×, Monovisc single 4 mL) :contentReference[oaicite:8]{index=8};
  • Dermal: follow aesthetic-specific protocols (typically one session, with optional follow-up) :contentReference[oaicite:9]{index=9}.
• Post-injection care:
  • Avoid strenuous activities for 48 hours (e.g., sports, heavy lifting) :contentReference[oaicite:10]{index=10};
  • Cold compress and rest treated area; observe for swelling, redness, or infection.
• Monitoring: Assess pain relief (joints) or cosmetic outcome and watch for local injection reactions :contentReference[oaicite:11]{index=11};
• Patient counseling: Advise delayed benefits (often after 1–3 weeks); reiterate technique, frequency, and side effects.

Mode of Action ALIAXIN EV

ALIAXIN EV works through physical, viscoelastic, and biochemical mechanisms:

• Viscosupplementation: Hydrophilic gel restores synovial fluid viscoelasticity, improving lubrication, shock absorption, and joint biomechanics :contentReference[oaicite:12]{index=12};
• Mechanical support: Creates a cushion that reduces cartilage wear and eases pain during movement :contentReference[oaicite:13]{index=13};
• Anti-inflammatory effects: May modulate inflammatory mediators, reduce nociceptor sensitivity, and inhibit pain pathways :contentReference[oaicite:14]{index=14};
• Tissue hydration and repair (cosmetic use): Binds water up to 1,000× its weight, swelling tissue for volume and creating an optimal environment for nutrient exchange and cell proliferation :contentReference[oaicite:15]{index=15};
• Biodegradable: Enzymatically broken down over time; effects are reversible and temporary :contentReference[oaicite:16]{index=16}.

ALIAXIN EV Interactions ALIAXIN EV

Hyaluronic acid injections generally exhibit minimal systemic interactions given localized action, but caution and awareness are advised in the following contexts:

• Local antiseptics: Avoid benzalkonium chloride (precipitation risk) :contentReference[oaicite:17]{index=17};
• Bleeding risk: Though no systemic interactions, avoid injections in patients taking anticoagulants or with bleeding disorders due to puncture risk :contentReference[oaicite:18]{index=18};
• Infection risk: Intra-articular injection in infected joints or overlying cellulitis is contraindicated—avoiding spread/inflammation :contentReference[oaicite:19]{index=19};
• Vaccinations: Avoid joint injection shortly before or after vaccination until local inflammation subsides :contentReference[oaicite:20]{index=20};
• Supplements/NSAIDs: No known direct interactions, but NSAIDs can alter bleeding risk and joint healing post-injection :contentReference[oaicite:21]{index=21}.

Integrating ALIAXIN EV into care requires clinical oversight, especially regarding aseptic technique and safe patient selection.

Dosage of ALIAXIN EV

• Joint (knee osteoarthritis):
  • Common regimens:
    • Synvisc: 16 mg/2 mL weekly × 3
    • Orthovisc: 30 mg/2 mL weekly × 3
    • Monovisc: 88 mg/4 mL single dose :contentReference[oaicite:22]{index=22};
  • Other options:
    • Supartz FX, GenVisc 850: 25 mg/2.5 mL weekly × 3–5
    • Hymovis: 24 mg/3 mL weekly × 2 :contentReference[oaicite:23]{index=23};
  • Tailored choice based on product concentration, cost, and disease severity.
• Aesthetic (dermal filler): Typical 1 mL per site; follow brand-specific protocols.
• Frequency:
  • Orthopedic: weekly injections depending on product;
  • Dermal: often single session with possible follow-up;
• Treatment cycle:
  • Repeat cycles every 6–12 months if symptoms reappear;
  • Monitor pain relief and function before repeating injections :contentReference[oaicite:24]{index=24}.
• Adjustments:
  • Avoid use in active infection or acute inflammation;
  • Use separate syringe for bilateral injections :contentReference[oaicite:25]{index=25};

Possible side effects of ALIAXIN EV

Local reactions are the most common side effects. Serious systemic events are rare:

• Common: Injection-site pain, swelling, redness, warmth, bruising, stiffness, mild effusion :contentReference[oaicite:26]{index=26};
• Local skin effects: Itching, rash, lumps or nodules in dermal use :contentReference[oaicite:27]{index=27};
• Musculoskeletal: Transient joint pain or stiffness post-injection present in ~25–90% cases; often resolves in days :contentReference[oaicite:28]{index=28};
• Serious: Rare infection, septic arthritis; very rare systemic allergic/anaphylaxis events :contentReference[oaicite:29]{index=29};
• Other: Headache, back pain, dizziness :contentReference[oaicite:30]{index=30};

Most mild effects subside within a week. Persistent symptoms or signs of infection require prompt medical attention, especially in joint injections.

ALIAXIN EV Contraindications ALIAXIN EV

• Absolute:
  • Allergy to hyaluronan or product components (including avian-derived in some brands) :contentReference[oaicite:31]{index=31};
  • Active infection in joint or overlying skin :contentReference[oaicite:32]{index=32};
  • Bleeding disorders or on anticoagulants (for intra-articular use) :contentReference[oaicite:33]{index=33};
• Relative (caution):
  • Severe joint effusion—drain fluid before injection :contentReference[oaicite:34]{index=34};
  • Lymphatic/venous stasis in extremity :contentReference[oaicite:35]{index=35};
  • Pregnancy/lactation: safety not established :contentReference[oaicite:36]{index=36};
  • Inflammatory arthritis may worsen temporarily after injection :contentReference[oaicite:37]{index=37};

Storage of ALIAXIN EV

• Temperature: Store at 2–25 °C (36–77 °F); do not freeze;
• Protection: Keep in original packaging, away from light and moisture;
• Sterility: Single-use syringe; discard after injection;
• Expiry: Check label and dispose upon expiry;
• Disposal: Sharps and syringe in approved biohazard containers.

Proper storage ensures sterility, product integrity, and patient safety.